Fusion Pharmaceuticals Inc. Quarterly Debt-to-equity in % from Q3 2021 to Q1 2024

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Fusion Pharmaceuticals Inc. quarterly Debt-to-equity history and growth rate from Q3 2021 to Q1 2024.
Fusion Pharmaceuticals Inc. Debt-to-equity for the quarter ending March 31, 2024 was 32.2 %, a 15.8% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q1 2024	32.2	+4.4	+15.8%	Mar 31, 2024
Q4 2023	31.8	+10.5	+49.3%	Dec 31, 2023
Q3 2023	33.5	+18.3	+121%	Sep 30, 2023
Q2 2023	32.5	+22.1	+214%	Jun 30, 2023
Q1 2023	27.8	+19.3	+225%	Mar 31, 2023
Q4 2022	21.3	+13.5	+174%	Dec 31, 2022
Q3 2022	15.2	+8.29	+120%	Sep 30, 2022
Q2 2022	10.4			Jun 30, 2022
Q1 2022	8.54			Mar 31, 2022
Q4 2021	7.79			Dec 31, 2021
Q3 2021	6.9			Sep 30, 2021

* An asterisk sign (*) next to the value indicates that the value is likely invalid.